Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-hour

Trial Profile

Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-hour

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2013

At a glance

  • Drugs Gatifloxacin (Primary) ; Moxifloxacin (Primary)
  • Indications Bacterial infections; Conjunctivitis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 12 Jun 2013 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 15 May 2007 Status change
    • 15 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top